Navigation Links
Ex-IITian-designed Alzheimer's Drug's Human Clinical Trials Begin

Purdue University researchers have begun the first phase of human clinical trials to test the efficacy of an Alzheimer's drug designed in-house.

The drug is based on an inhibitor developed by a team of researchers at the university. The researchers say that it may help intercept and disable the disease at an early stage.

"Millions of people suffer from this devastating disease and treatment options are very limited," said Professor Arun Ghosh, who led the creation of the treatment molecule.

"Current drugs manage the symptoms, but this could be the first disease-modifying therapy. It may be able to prevent and reverse the disease," Ghosh, who did his MSc from MSc, Indian Institute of Technology, Kanpur in 1981.

CoMentis Inc., a San Francisco-based biopharmaceutical firm co-founded by Professor Ghosh and Oklahoma Medical Research Foundation (OMRF) scientist Jordan Tang, is initiating the clinical trials of the experimental drug CTS-21166.

The trial, which comprises of 48 healthy volunteers, will measure safety, tolerability, and pharmacokinetics of CTS-21166 at various doses.

Its results are expected to be out by the end of 2007, and the researchers expect to begin phase II studies in Alzheimer's patients in 2008.

In 2000, Professor Ghosh had built an inhibitor that had the ability to bind to and inactivate the beta-secretase enzyme, which is significant to the progression of Alzheimer's. Since then he has been leading the structure-based design of these inhibitors for therapeutic intervention of the disease.

His most recent work, which led to the creation of beta-secretase inhibitor CTS-21166, was published in the Journal of Medicinal Chemistry.

"The molecule is both highly potent and highly selective, meaning it does not appear to affect other enzymes important to brain function or cause harmful side effects," Professor Ghosh said.

"It took years of work and evaluation of hundreds of molecules to achieve one with the strength and safety necessary for clinical potential," he added.


'"/>




Related medicine news :

1. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
2. Decrease in testosterone levels lead to Alzheimers
3. Smokers are prone to Alzheimers
4. Over-The-Counter Drugs May Prevent Alzheimers
5. Alzheimers followed by head injury
6. Vitamin E useful for Alzheimers
7. Staying mentally energitic prevents Alzheimers
8. Researchers trick Alzheimers Enzyme
9. Drug Offers Hope for Alzheimers disease
10. Alzheimers with psychosis runs in families
11. Blood test may aid foretell Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of ... its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his ... July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming ...
(Date:10/13/2017)... Ill. (PRWEB) , ... October ... ... Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer ... healthcare professionals on guideline updates for the primary prevention of cardiovascular diseases ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Global Healthcare ... scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare ... activity. The fun run is geared towards children of all ages; it is ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
Breaking Medicine Technology: